Advertisement
Screener

BridgeBio Pharma, Inc. (BBIO) Graph

BBIO Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2019-06-30: Operating expenses $69.00K; Net income -$69.00K.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

BBIO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.License And Service$5.80MProduct$222.44MRoyalty$15.43MRevenue$243.68MCost of revenue$15.05MOperating income-$107.08MOther income, net$5.59MResearch & development$149.45MSelling, general& administrative$186.26MPre-tax income-$155.89MIncome tax$0.00Net income-$155.89M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

BBIO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$243.68MRevenue$243.68MCost of revenue$15.05MOperating income-$107.08MOther income, net$5.59MResearch & development$149.45MSelling, general& administrative$186.26MPre-tax income-$155.89MIncome tax$0.00Net income-$155.89M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 1 month

Period endOperating expensesNet income
2019-06-30$69.00K-$69.00K

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome tax
2026-06-30$243.68M$15.05M$149.45M$186.26M(m)$0.00
2026-03-31$194.51M$9.94M$126.64M$163.90M(m)(m)
2025-12-31$154.18M*$8.11M*$116.42M*$158.09M*(m)-$120.00K*
2025-09-30$120.70M$6.56M$112.87M$137.62M(m)-$1.54M
2025-06-30$110.56M$3.65M$111.23M$129.15M(m)$2.10M
2025-03-31$116.63M$2.64M$111.43M$106.36M(m)$0.00
2024-09-30$2.73M$598.00K$120.44M$68.82M(m)$0.00
2024-06-30$2.17M$598.00K$114.69M$59.52M(m)$0.00
2024-03-31$211.12M$598.00K$140.97M$65.81M(m)$0.00
2023-09-30$4.09M$598.00K$125.14M$35.78M(m)$0.00
2023-06-30$1.64M$599.00K$107.49M$36.12M(m)$0.00
2023-03-31$1.83M$651.00K$92.86M$31.11M(m)$0.00
2022-09-30$338.00K$739.00K$92.51M$31.19M(m)$0.00
2022-06-30$73.75M$700.00K$108.40M$36.43M(m)$0.00
2022-03-31$1.69M(m)$107.65M$43.71M(m)$0.00
2021-09-30$2.34M$1.45M$104.31M$46.08M(m)$0.00
2021-06-30$54.02M$109.00K$101.96M$45.97M(m)$0.00
2021-03-31$462.00K(m)$122.56M$45.41M$167.97M$0.00
2020-12-31(m)(m)(m)(m)$127.61M*(m)
2020-09-30$8.13M$0.00$92.05M$36.02M$128.07M$0.00
2020-06-30(m)(m)$86.60M$37.97M$124.57M$0.00
2020-03-31(m)(m)$68.22M(m)$102.49M$0.00
2019-09-30$26.74M(m)$55.28M(m)$81.27M(m)
2019-06-30(m)(m)$52.33M(m)$69.32M(m)
2019-03-31(m)(m)$44.85M(m)$63.75M(m)
2018-09-30(m)(m)$31.15M(m)$41.46M(m)

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome tax
2026-06-30$438.19M$24.98M$276.08M$350.16M(m)$0.00
2025-06-30$227.20M$6.29M$222.66M$235.52M(m)$2.10M
2024-06-30$213.29M$1.20M$255.67M$125.33M(m)$0.00
2023-06-30$3.47M$1.25M$200.35M$67.23M(m)$0.00
2022-06-30$75.44M$2.05M$216.05M$80.14M(m)$0.00
2021-06-30$54.49M$109.00K$224.52M$91.38M(m)$0.00
2020-06-30(m)(m)$154.82M$72.23M$227.05M$0.00
2019-06-30(m)(m)$97.18M(m)$133.07M(m)

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome tax
2025-09-30$347.90M$12.86M$335.54M$373.14M(m)$555.00K
2024-09-30$216.02M$1.79M$376.11M$194.15M(m)$0.00
2023-09-30$7.56M$1.85M$325.49M$103.01M(m)$0.00
2022-09-30$75.78M$2.79M$308.56M$111.33M(m)$0.00
2021-09-30$56.83M$1.56M$328.82M$137.46M(m)$0.00
2020-09-30$8.13M$0.00$246.87M$108.25M$355.12M$0.00
2019-09-30$26.74M(m)$152.46M(m)$214.34M(m)
2018-09-30(m)(m)$88.87M(m)$118.08M(m)

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome tax
2025-12-31$502.08M$20.96M$451.95M$531.23M(m)$435.00K
2024-12-31$221.90M$3.88M$506.46M$288.93M(m)$1.15M
2023-12-31$9.30M$2.45M$455.71M$150.59M(m)$0.00
2022-12-31$77.65M$3.43M$399.46M$143.19M(m)$0.00
2021-12-31$69.72M$3.11M$451.02M$192.21M(m)(m)
2020-12-31$8.25M(m)$337.05M$145.68M$482.73M(m)
2019-12-31$40.56M(m)$209.95M$94.35M$306.80M(m)
2018-12-31(m)(m)$140.07M(m)$183.66M(m)
2017-12-31(m)(m)$30.56M(m)$43.86M(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52